Karo Pharma Quarterly report Q3 2021
July – September · Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period. · The organic growth[1] during the third quarter was +13%. The currency impact in the quarter was 0% while the divestments generated an effect of -4%. · EBIT (Operating Profit) amounted to MSEK 99.5 (43.7), corresponding to an increase of 127%. · EBITDA[1] (Operating Profit after depreciation and amortization) amounted to MSEK 234.5 (174.8) corresponding to an increase of 34%. · The gross margin[1], defined as gross profit divided by revenues, was 56.4% (57.8%).